ArticleAmerican journal of hematology2014

Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia.

Lori A Gardner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.